Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Current Deferred Revenue (2018 - 2025)

Historic Current Deferred Revenue for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to $12.3 million.

  • Bicycle Therapeutics' Current Deferred Revenue rose 776.06% to $12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.3 million, marking a year-over-year increase of 776.06%. This contributed to the annual value of $10.2 million for FY2024, which is 5920.01% down from last year.
  • Latest data reveals that Bicycle Therapeutics reported Current Deferred Revenue of $12.3 million as of Q3 2025, which was up 776.06% from $14.6 million recorded in Q2 2025.
  • Over the past 5 years, Bicycle Therapeutics' Current Deferred Revenue peaked at $29.8 million during Q2 2023, and registered a low of $8.7 million during Q2 2021.
  • Its 5-year average for Current Deferred Revenue is $17.2 million, with a median of $16.4 million in 2024.
  • In the last 5 years, Bicycle Therapeutics' Current Deferred Revenue surged by 14277.77% in 2021 and then tumbled by 6094.98% in 2024.
  • Bicycle Therapeutics' Current Deferred Revenue (Quarter) stood at $19.3 million in 2021, then increased by 5.94% to $20.4 million in 2022, then increased by 22.33% to $25.0 million in 2023, then tumbled by 59.2% to $10.2 million in 2024, then grew by 20.31% to $12.3 million in 2025.
  • Its Current Deferred Revenue stands at $12.3 million for Q3 2025, versus $14.6 million for Q2 2025 and $12.5 million for Q1 2025.